急性髓系白血病患者血清HGF、Flt3L、MIP-1α水平及其与预后的关系  

Serum Levels of HGF, Flt3L, MIP-1α in Patients with Acute Myeloid Leukemia and Its Relationship with Prognosis

作　　者：朱贺[1] 司雯雯 刘进伟 ZHU He;SI Wenwen;LIU Jinwei(Clinical Laboratory,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China;Pharmaceutical Dispensing Department,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,China)

机构地区：[1]河南科技大学第一附属医院检验科,河南洛阳471000 [2]河南科技大学第一附属医院药品调剂科,河南洛阳471000

出　　处：《河南医学研究》2024年第23期4290-4294,共5页Henan Medical Research

摘　　要：目的探讨急性髓系白血病患者血清肝细胞生长因子(HGF)、FMS样酪氨酸激酶3配体(Flt3L)、巨噬细胞炎症蛋白-1α(MIP-1α)水平及其与预后的关系。方法回顾性选取102例2020年5月至2022年1月河南科技大学第一附属医院收治的急性髓系白血病患者的临床资料作为病例组,所选患者均行规范化治疗,均治疗8周,并随访1 a,根据近期疗效的不同将所选患者分为未缓解组(28例)、部分缓解组(45例)和完全缓解组(29例),并根据远期预后的不同将所选患者分为预后不良组(34例)和预后良好组(68例),另选115例同期收治的健康志愿者作为对照组。比较病例组和对照组、急性髓系白血病患者治疗前和治疗8周后、不同近期疗效和远期预后急性髓系白血病患者血清HGF、Flt3L、MIP-1α水平,绘制受试者工作特征(ROC)曲线,分析血清HGF、Flt3L、MIP-1α对急性髓系白血病患者远期预后不良的预测价值。结果病例组血清HGF、MIP-1α水平高于对照组(P<0.05),血清Flt3L水平低于对照组(P<0.05)。治疗8周后,急性髓系白血病患者血清HGF、MIP-1α水平低于治疗前(P<0.05),血清Flt3L水平高于治疗前(P<0.05)。未缓解组血清HGF、MIP-1α水平高于部分缓解组和完全缓解组(P<0.05),部分缓解组高于完全缓解组(P<0.05);未缓解组血清Flt3L水平低于部分缓解组和完全缓解组(P<0.05),部分缓解组低于完全缓解组(P<0.05)。预后不良组血清HGF、MIP-1α水平高于预后良好组(P<0.05);血清Flt3L水平低于预后良好组(P<0.05)。血清HGF、Flt3L、MIP-1α联合检测诊断急性髓系白血病患者远期预后不良的曲线下面积(AUC)为0.937,高于血清HGF、Flt3L、MIP-1α单独检测(0.817、0.713、0.801,P<0.05)。结论血清HGF、MIP-1α水平在急性髓系白血病患者中呈高表达,而血清Flt3L水平呈低表达,三者水平变化对急性髓系白血病患者近期疗效和远期预后评估具有一定指导作用,且三者联合检测对急Objective To investigate the serum levels of hepatocyte growth factor(HGF),FMS-like tyrosine kinase 3 ligand(Flt3L),and macrophage inflammatory protein-1αin patients with macrophage inflammatory protein 1(MIP-1)and their relationship with prognosis.Methods The clinical data of 102 patients with acute myeloid leukemia admitted to the First Affiliated Hospital of Henan University of Science and Technology from May 2020 to January 2022 were retrospectively selected as the case group.All patients were treated with standardized treatment for 8 weeks,and were followed up for 1 year.The selected patients were divided into non remission group(28 cases),the partial remission group(45 cases),and the complete remission group(29 cases)according to the short term efficacy,the selected patients were divided into the poor prognosis group(34 cases)and the good prognosis group(68 cases)according to the long-term prognosis,with an additional 115 healthy volunteers admitted during the same period as the control group.The serum levels of HGF,Flt3L,and MIP-1αin the case group and the control group,in patients with acute myeloid leukemia before and after 8 weeks of treatment,as well as in patients with different short term efficacy and long-term prognosis were compared,draw receiver operating characteristic(ROC)curve and the serum HGF,Flt3L,MIP-1αfor the predictive value of poor long-term prognosis in patients with acute myeloid leukemia were analyzed.Results Serum levels of HGF and MIP-1αin the case group were higher than the control group(P<0.05);the serum level of Flt3L was lower than the control group(P<0.05).After 8 weeks of treatment,serum levels of HGF and MIP-1αin patients with acute myeloid leukemia were lower than before treatment(P<0.05),the serum level of Flt3L was higher than before treatment(P<0.05).Serum levels of HGF and MIP-1αin the non remission group were higher than the partial remission group and the complete remission group(P<0.05),and the partial remission group was higher than the complete remission group

关 键 词：急性髓系白血病 肝细胞生长因子 FMS样络氨酸激酶3配体 巨噬细胞炎症蛋白-1Α 疗效 预后 预测价值 

分 类 号：R55[医药卫生—血液循环系统疾病]